Although the authors did not report the proportion of mice that responded to the combination treatment, the synergistic effects on tumour shrinkage indicate a potential benefit of combining bendamustine with selinexor, likely due to the nuclear retention of p53 sensitizing the cells to chemotherapy. Here, TP53 is linked to neoplasm.